Objectives of Programme's Learning Outcomes

• Scientific skills
• Implement and independently carry out an experimental approach, validate a model by comparing its predications with experimental results, assess the limitations of the model's validity, and identify sources or error.
• Professional integration skills
• Invest their knowledge and skills in professional scenarios

Learning Outcomes of UE

First-line cancer treatment. The course will be teached in english.

UE Content: description and pedagogical relevance

This course will develop the systemic treatment of cancer including chemotherapy, hormone therapy, targeted therapies (against signaling pathways and mutations), and immunotherapy. Cancer chemotherapy uses drugs that interfere with cell growth leading to cell death (cytotoxic drugs) or stopping cell proliferation (cytostatic drugs). This course will also discuss the importance of multidrug therapy. In the context of integrative oncology, the coordination of care between the pharmacist, the doctor and the hospital is important. The efficacy of anticancer treatments and the associated adverse effects will be discussed, in particular concerning the dermatological toxicity of oncological treatments. Finally, the role of pharmacists in supportive care will be presented.
 

Prior Experience

Not applicable

Type(s) and mode(s) of Q1 UE assessment

• Oral examination - Face-to-face

Q1 UE Assessment Comments

None

Method of calculating the overall mark for the Q1 UE assessment

/

Type(s) and mode(s) of Q1 UE resit assessment (BAB1)

• Oral examination - Face-to-face

Q1 UE Resit Assessment Comments (BAB1)

None

Method of calculating the overall mark for the Q1 UE resit assessment

/

Type(s) and mode(s) of Q3 UE assessment

• Oral examination - Face-to-face

Q3 UE Assessment Comments

None

Method of calculating the overall mark for the Q3 UE assessment

/